February 19, 2021 11:22 AM ESTUpdated 02:10 PM

After crossing t's, dotting i's, Immunocore nails down breakthrough therapy designation for lead TCR therapy

Nicole DeFeudis

Editor

Days after tapping a new commercial head, Immunocore has scored a breakthrough therapy designation for its lead T cell receptor program, which it plans on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After crossing t's, dotting i's, Immunocore nails down breakthrough therapy designation for lead TCR therapy

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Af­ter cross­ing t's, dot­ting i's, Im­muno­core nails down break­through ther­a­py des­ig­na­tion for lead TCR ther­a­py

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

After crossing t's, dotting i's, Immunocore nails down breakthrough therapy designation for lead TCR therapy